President Barack Obama's highly anticipated BRAIN initiative--short for Brain Research Through Advancing Innovative Neurotechnologies--has the lofty goal of mapping the human brain in hopes of finding new treatments for diseases like Alzheimer's, Parkinson's and other neurological disorders.
Astellas Pharma has wagered on antibody drug conjugate tech from the San Diego biotech startup Ambrx, paying $15 million upfront and committing up to $285 million more in their collaboration focused in oncology. And it's more proof that major pharma outfits are keen on the advantages of pairing targeted antibodies with potent drug payloads to treat cancer.
Agios has teamed up with Foundation Medicine to find patients with the genetic profiles most suited to treatment on Agios therapies concerning two cancer metabolism targets.
Just a few months after inking a tie-up with Amgen, Bind Therapeutics has come back from the deal table with another marquee partner looking to use its nanoengineering platform to launch newly amped-up treatments into the clinic.
A consortium of 14 academic and industrial research teams have joined up to form AgedBrainSYSBIO, a collaborative research project aimed at investigating chronic neurodegenerative disorders like Alzheimer's disease.
After a pair of trial setbacks with a separate program from ArQule, Japan-based drugmaker Daiichi Sankyo has decided to jettison an alliance with the Woburn, MA-based drug developer on an early-stage compound known as ARQ 092.
In the face of declining demand for diagnostic tests, LabCorp is focusing on its testing unit, signing a lab services and biomarker study deal with Bristol-Myers Squibb.
ReSearch Pharmaceutical Services is teaming up with Japan's Asklep to kick off a joint venture targeting the country's growing biotech and medical device industries.
Sony and Olympus in Japan are putting off indefinitely their highly touted partnership to concoct new endoscopes and other medical devices. The delay stems from continued Chinese regulatory snafus.
Edison Pharmaceuticals shed its stealth mode and went public with a $545 million-plus collaboration deal with Japan's Dainippon Sumitomo that centers on its lead late-stage drug for rare diseases.